We are excited to share that our latest case report has been accepted for publication in Vaccines!
Cancer neoantigens arising from somatic mutations have emerged as important targets for personalized immunization. Here, we report improved overall survival in a HER2-positive metastatic breast cancer patient treated with our personalized peptide immunization, BiTAP (Bioinformatic Therapy Address Peptides). Epitopes were predicted using our in-house bioinformatics pipeline, and immunogenicity was evaluated using IFN-γ ELISPOT and intracellular cytokine staining assays.
Overall, a significant peptide-specific T-cell response was observed against 18 of the 76 peptides tested (≈24%). Patient follow-up via serological markers showed a marked reduction in tumor marker levels following BiTAP immunization. In combination with standard therapy, BiTAP treatment was associated with stable disease, notable improvement in overall survival, and no serious treatment-related adverse effects.
These findings demonstrate that BiTAP immunization is feasible and safe and highlight its potential to induce tumor regression in patients with HER2-positive breast cancer.
We are deeply grateful to everyone who contributed to making this work possible.
Back to all updates